Skip to content

King Pharmaceuticals KG Commercial Auto Liability — Year 1

Other product segments

All other lines
57%
International
41.8%
General Liability
5.9%
European Hospital Liability
3.2%

Similar metrics at other companies

Kemper logo
KMPRCommercial Automobile Insurance—Liability — Year 1
19.1%-2.4pp
CNA Financial logo
CNACommercial Auto — Year 1
22.6%-1.1pp
United Fire Group logo
UFCSCommercial automobile — Year 1
35.7%-0.3pp
United Fire Group logo
UFCSCommercial other liability — Year 1
7.1%-0.5pp
Kemper logo
KMPRCommercial Automobile Insurance—Physical Damage — Year 1
87.2%+1.8pp
Horace Mann Educators logo
HMNAutomobile Liability — Year One
37.1%-0.1pp

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-67.6%
Enterprise value$184.93M-50.0%
P/E1.2×
P/S1.6×-24.3×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's commercial auto liability — year 1.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's commercial auto liability — year 1?
King Pharmaceuticals (KG) reported commercial auto liability — year 1 of 11.9% in Q4 2025.
What does commercial auto liability — year 1 mean?
This metric represents the loss development or financial performance data for the commercial auto liability segment specifically for the first year of the policy cycle. It is used to track early-stage claims emergence and underwriting results. Comparing this across years helps identify shifts in initial loss expectations.